One noteworthy finding of this study is that ERRα could be druggable as the intracellular DHT production and AR signaling in prostate cancer cells could be significantly attenuated or suppressed by treatment with XCT790, likely via its direct repression on AKR1C3 enzyme and reduction of ERRα protein level. The gene discussed is AR; the disease is prostate cancer.